Thrombopoietin receptor agonists in pharmacotherapy of pediatric immune thrombocytopenia

Introduction: Thrombopoietin receptor agonists are commonly second-line drugs in immune thrombocytopenia (ITP) pharmacotherapy children and prescribed for chronic ITP refractory to first-line therapy.
 Standard children: includes prescribing glucocorticoids or intravenous immunoglobulins.
 agonists: Currently Romiplostim Eltrombopag used the Russian Federation pediatrics. Their pharmacodynamic features comparison with other presented paper. Increased thrombocytopoiesis is dominant, but not only component of mechanism action. It relevant study their effect on tolerance ITP, which may be associated a persistent platelet response some patients after drug discontinuation.
 Conclusion: The issue thrombopoietin agonist efficacy safety as well mode use treatment continues studied. high cost limiting factor earlier prescription. Generic – partly solve problem, promote prescription require additional bioequivalence therapeutic equivalence original drugs.
 Graphical Abstract